Tezspire 210 mg solution for injection in pre-filled syringe
D5242C00002
Phase 3 small_molecule active
Quick answer
Tezspire 210 mg solution for injection in pre-filled syringe for Chronic Rhinosinusitis with Nasal Polyposis is a Phase 3 program (small_molecule) at AstraZeneca AB with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AstraZeneca AB
- Indication
- Chronic Rhinosinusitis with Nasal Polyposis
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active